Here are the latest quarterly results of Cadila Healthcare. For more details, see the Cadila Healthcare financial fact sheet and Cadila Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 35,779 | 37,328 | 34,963 | 33,666 | 36,381 | 37,521 | 36,399 | 38,200 | |
Other income | Rs m | 310 | 384 | 226 | 269 | 201 | 443 | 225 | 275 | |
Turnover | Rs m | 36,089 | 37,712 | 35,189 | 33,935 | 36,582 | 37,964 | 36,624 | 38,475 | |
Expenses | Rs m | 27,380 | 29,324 | 28,643 | 27,410 | 29,449 | 29,609 | 28,245 | 29,566 | |
Gross profit | Rs m | 8,399 | 8,004 | 6,320 | 3,575 | 6,916 | 7,387 | 8,154 | 7,314 | |
Depreciation | Rs m | 1,537 | 1,556 | 1,716 | 1,723 | 1,741 | 1,785 | 1,768 | 1,790 | |
Interest | Rs m | 455 | 773 | 891 | 897 | 805 | 825 | 677 | 457 | |
Profit before tax | Rs m | 6,717 | 6,059 | 3,939 | 1,224 | 4,571 | 5,220 | 5,934 | 5,342 | |
Tax | Rs m | 1,586 | 1,267 | 791 | 395 | 927 | 1,085 | 1,235 | 1,106 | |
Profit after tax | Rs m | 5,131 | 4,792 | 3,148 | 829 | 3,644 | 4,135 | 4,699 | 4,236 | |
Gross profit margin | % | 23.5 | 21.4 | 18.1 | 10.6 | 19.0 | 19.7 | 22.4 | 19.1 | |
Effective tax rate | % | 23.6 | 20.9 | 20.1 | 32.3 | 20.3 | 20.8 | 20.8 | 20.7 | |
Net profit margin | % | 14.3 | 12.8 | 9.0 | 2.5 | 10.0 | 11.0 | 12.9 | 11.1 | |
Diluted EPS | Rs | 5.0 | 4.7 | 3.1 | 0.8 | 3.6 | 4.0 | 4.6 | 4.1 | |
Diluted EPS (TTM) | Rs | 19.2 | 17.9 | 16.7 | 13.6 | 12.1 | 11.5 | 13.0 | 16.3 | |
![]() |
Read: Cadila Healthcare 1QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: AJANTA PHARMA VENUS REMEDIES PIRAMAL ENTERPRISES ASTRAZENECA PHARMA UNICHEM LAB
Compare CADILA HEALTHCARE With: AJANTA PHARMA VENUS REMEDIES PIRAMAL ENTERPRISES ASTRAZENECA PHARMA UNICHEM LAB
Compare CADILA HEALTHCARE With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 390 points, down 0.8% at 48,644 levels.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More